Lead-212 PSV359 Therapy for Patients With Solid Tumors
Status:
RECRUITING
Trial end date:
2032-05-28
Target enrollment:
Participant gender:
Summary
Phase I/IIa clinical study evaluating the safety and efficacy of peptide-based theranostic (therapeutic and diagnostic) radiopharmaceuticals, i.e. \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 targeting Fibroblast Activation Protein in subjects with solid tumors.